Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: Synthesis of the antifungal agent cilofungin (LY121019)

59Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

The antifungal antibiotic, echinocandin B (ECB), was modified by a sequential procedure in which the initial step involved enzymatic removal of the native N-linoleoyl group from the N-terminus using an Actinoplanes utahensis culture. The resulting product, ECB nucleus, was reacylated using active esters or acid halides of various substituted acids to give a series of ECB analogs. These analogs possessed anti-Candida activity both in vitro and in vivo (mice). Other studies have shown that one of these, cilofungin, the 4-n-octyloxybenzoyl-ECB analog (LY121019), has excellent anti-Candida activity, low toxicity and is superior to other available antifungal antibiotics. © 1989, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. All rights reserved.

Cite

CITATION STYLE

APA

Debono, M., Abbott, B. J., Fukuda, D. S., Barnhart, M., Willard, K. E., Molloy, R. M., … Hunt, A. H. (1989). Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: Synthesis of the antifungal agent cilofungin (LY121019). The Journal of Antibiotics, 42(3), 389–397. https://doi.org/10.7164/antibiotics.42.389

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free